The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Headwaters Capital sees deep value in Bio-Techne as academic cuts weigh on shares. Learn why this life sciences leader could ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

The OTCQB Venture Virtual Investor Conference is hosted by VirtualInvestorConferences.com. Telo Genomics will present live on Thursday, August 7 th at 1:00 pm – 1:30 pm ET. Investors can register for ...